Immunovant, Inc.
NASDAQImmunovant heads into its May 29 earnings event with the positioning picture reversed from a week ago — options traders have rotated from aggressive call buying to measurable put demand, even as the stock has surged nearly 29% over the past week to $33.83. The shift in options is the sharpest change since the previous notes. The put/call ratio has climbed to 0.31, more than two…
Snapshot as of 5 Jul 2026
Immunovant heads into its May 29 earnings event with the positioning picture reversed from a week ago — options traders have rotated from aggressive call buying to measurable put demand, even as the stock has surged…
Immunovant heads into its May 29 earnings event with one of the most polarised positioning setups in the biotech space — aggressive call buying on one side, stubborn short sellers and a parade of executive sales on the…
Immunovant is heading into its May 29 earnings event carrying a sharply split set of signals — an unusually bullish options print colliding with a stubborn double-digit short position and a month of executive…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IMVT — free to start on ORTEX.
Sign up for free →Open IMVT on ORTEX